If similar results are seen in human clinical samples, our demonstration of increased TGF-β1 protein and decreased TGF-β3 protein in the mammary tumors raise the possibility that TGF-β pathway antagonists that spare TGF-β3 may have advantages over pan-isoform-specific inhibitors in breast cancer therapy. This evidence concerns the gene TGFB1 and breast carcinoma.